Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have earned a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $38.9286.

VRDN has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. The Goldman Sachs Group restated a “buy” rating and set a $39.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Truist Financial raised their target price on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Stifel Nicolaus set a $39.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. Finally, Wedbush boosted their target price on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th.

Institutional Trading of Viridian Therapeutics

Several large investors have recently modified their holdings of the company. Perceptive Advisors LLC lifted its holdings in Viridian Therapeutics by 108.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after acquiring an additional 1,580,303 shares during the period. Morgan Stanley grew its stake in shares of Viridian Therapeutics by 805.6% during the 4th quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock valued at $54,094,000 after purchasing an additional 1,546,284 shares during the period. Avoro Capital Advisors LLC bought a new stake in shares of Viridian Therapeutics during the 4th quarter valued at about $46,680,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at about $25,306,000. Finally, Vanguard Group Inc. increased its position in shares of Viridian Therapeutics by 29.6% during the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after purchasing an additional 1,280,161 shares during the last quarter.

Viridian Therapeutics Trading Up 4.6%

Viridian Therapeutics stock opened at $23.09 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. Viridian Therapeutics has a one year low of $13.18 and a one year high of $34.29. The stock has a market capitalization of $2.62 billion, a PE ratio of -6.85 and a beta of 0.91. The business’s fifty day moving average is $19.16 and its 200 day moving average is $21.16.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The business had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. On average, sell-side analysts predict that Viridian Therapeutics will post -4.07 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.